{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PROSTVAC-F&page=2", "query": { "intervention": "PROSTVAC-F", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PROSTVAC-F&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-18T02:11:08.898Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01322490", "title": "A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostate Cancer Metastatic" ], "interventions": [ { "name": "PROSTVAC-V", "type": "BIOLOGICAL" }, { "name": "PROSTVAC-F", "type": "BIOLOGICAL" }, { "name": "GM-CSF", "type": "DRUG" }, { "name": "GM-CSF Placebo", "type": "OTHER" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "Bavarian Nordic", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 1297, "start_date": "2011-11-28", "completion_date": "2017-12-15", "has_results": true, "last_update_posted_date": "2019-09-04", "last_synced_at": "2026-09-18T02:11:08.898Z", "location_count": 84, "location_summary": "Anchorage, Alaska • Scottsdale, Arizona • Berkeley, California + 68 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Berkeley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Marina del Rey", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01322490" }, { "nct_id": "NCT00020254", "title": "Vaccine Therapy Plus Sargramostim and Interleukin-2 Compared With Nilutamide Alone in Treating Patients With Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "aldesleukin", "type": "BIOLOGICAL" }, { "name": "recombinant fowlpox-prostate specific antigen vaccine", "type": "BIOLOGICAL" }, { "name": "recombinant vaccinia prostate-specific antigen vaccine", "type": "BIOLOGICAL" }, { "name": "recombinant vaccinia-B7.1 vaccine", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "nilutamide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": null, "start_date": "2000-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-04-29", "last_synced_at": "2026-09-18T02:11:08.898Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00020254" }, { "nct_id": "NCT00078585", "title": "PROSTVAC®-VF/TRICOM™ Vaccine for the Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "PROSTVAC®-VF/TRICOM™", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Bavarian Nordic", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 120, "start_date": "2003-11", "completion_date": "2009-01", "has_results": false, "last_update_posted_date": "2017-09-11", "last_synced_at": "2026-09-18T02:11:08.898Z", "location_count": 47, "location_summary": "Homewood, Alabama • Anchorage, Alaska • Fresno, California + 41 more", "locations": [ { "city": "Homewood", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Fresno", "state": "California" }, { "city": "La Mesa", "state": "California" }, { "city": "Loma Linda", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00078585" }, { "nct_id": "NCT02326805", "title": "PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active Surveillance", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage I Prostate Adenocarcinoma AJCC v7", "Stage II Prostate Adenocarcinoma AJCC v7" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Placebo Administration", "type": "OTHER" }, { "name": "Rilimogene Galvacirepvec", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "MALE", "summary": "Male only" }, "enrollment_count": 154, "start_date": "2015-06-03", "completion_date": "2022-07-20", "has_results": true, "last_update_posted_date": "2023-07-19", "last_synced_at": "2026-09-18T02:11:08.898Z", "location_count": 7, "location_summary": "Los Angeles, California • Newport Beach, California • Orange, California + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02326805" }, { "nct_id": "NCT00005039", "title": "Vaccine Therapy in Treating Patients With Advanced Adenocarcinoma of the Prostate (Prostate Cancer)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarcinoma of the Prostate", "Recurrent Prostate Cancer", "Stage IV Prostate Cancer" ], "interventions": [ { "name": "recombinant fowlpox-prostate specific antigen vaccine", "type": "BIOLOGICAL" }, { "name": "recombinant vaccinia prostate-specific antigen vaccine", "type": "BIOLOGICAL" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 86, "start_date": "2000-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-24", "last_synced_at": "2026-09-18T02:11:08.898Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005039" }, { "nct_id": "NCT00113984", "title": "Vaccine and Antibody Treatment of Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostatic Neoplasms" ], "interventions": [ { "name": "PROSTVAC-V/TRICOM", "type": "BIOLOGICAL" }, { "name": "PROSTVAC-F/TRICOM", "type": "BIOLOGICAL" }, { "name": "MDX-010", "type": "DRUG" }, { "name": "Sargramostim", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "MALE", "summary": "18 Years to 85 Years · Male only" }, "enrollment_count": 30, "start_date": "2005-06-08", "completion_date": "2011-12-01", "has_results": false, "last_update_posted_date": "2019-12-16", "last_synced_at": "2026-09-18T02:11:08.898Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00113984" }, { "nct_id": "NCT00045227", "title": "Vaccine Therapy With or Without Docetaxel in Treating Patients With Metastatic Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "recombinant fowlpox-prostate specific antigen vaccine", "type": "BIOLOGICAL" }, { "name": "recombinant vaccinia prostate-specific antigen vaccine", "type": "BIOLOGICAL" }, { "name": "recombinant vaccinia-B7.1 vaccine", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "docetaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": null, "start_date": "2002-08", "completion_date": "2007-10", "has_results": false, "last_update_posted_date": "2013-06-19", "last_synced_at": "2026-09-18T02:11:08.898Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00045227" }, { "nct_id": "NCT02506114", "title": "Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostatic Neoplasms" ], "interventions": [ { "name": "PROSTVAC V/F", "type": "BIOLOGICAL" }, { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Lawrence Fong", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 15, "start_date": "2016-10-06", "completion_date": "2020-04-22", "has_results": true, "last_update_posted_date": "2021-11-24", "last_synced_at": "2026-09-18T02:11:08.898Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02506114" }, { "nct_id": "NCT04020094", "title": "Perioperative Atezolizumab With MVA-BN-Brachyury and PROSTVAC For Intermediate-Risk And High-Risk Localized Prostate Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Adenocarcinoma" ], "interventions": [ { "name": "MVA-BN-Brachyury", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 0, "start_date": "2019-11-20", "completion_date": "2021-04-09", "has_results": false, "last_update_posted_date": "2021-09-22", "last_synced_at": "2026-09-18T02:11:08.898Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT04020094" }, { "nct_id": "NCT01145508", "title": "Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hormone-Resistant Prostate Cancer", "Prostate Adenocarcinoma", "Recurrent Prostate Carcinoma", "Stage IV Prostate Cancer" ], "interventions": [ { "name": "Docetaxel", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine", "type": "BIOLOGICAL" }, { "name": "Rilimogene Galvacirepvec", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 10, "start_date": "2010-08", "completion_date": "2015-10", "has_results": true, "last_update_posted_date": "2017-09-19", "last_synced_at": "2026-09-18T02:11:08.898Z", "location_count": 14, "location_summary": "Jacksonville, Florida • Chicago, Illinois • Highland Park, Illinois + 10 more", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Highland Park", "state": "Illinois" }, { "city": "Kankakee", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01145508" } ] }